The University of British Columbia
UBC - A Place of Mind
The University of British Columbia Okanagan campus
UBC Okanagan News
  • Home
  • Services for Media
  • Faculty and Staff
  • Submit Your Story
  • Events
  • Contact
Home / 2017 / February / 27 / Given the choice, patients will reach for cannabis over prescribed opioids

Given the choice, patients will reach for cannabis over prescribed opioids

By Christine Zeindler on February 27, 2017

New research suggests people with chronic pain would rather use cannabis over their recommended medicine.

New research suggests people with chronic pain would rather use cannabis over their recommended medicine.

Chronic pain sufferers and those taking mental health meds would rather turn to cannabis instead of their prescribed opioid medication, according to a new study.

“This study is one of the first to track medical cannabis use under the new system of licensed producers, meaning that all participants had physician authorization to access cannabis in addition to their prescription medicines,” says UBC Assoc. Prof. Zach Walsh, co-author of the study.

The study tracked more than 250 patients with prescribed medical cannabis—people treated for conditions such as chronic pain, mental health and gastrointestinal issues. Overall, 63 per cent of respondents reported using cannabis instead of their prescription drugs, which included opioids (to treat pain), benzodiazepines (sedatives) and anti-depressants.

Study lead Philippe Lucas is vice-president of Patient Research and Access at Tilray, a federally authorized medical cannabis production and research company, and a doctoral student at the University of Victoria Centre for Addictions Research of BC. Lucas suggests the main reasons for the switch to cannabis from prescribed meds is due to reduced side effects, better symptom management and a feeling that cannabis is safer than prescription drugs.

Walsh goes on to suggest cannabis may have an important role to play in addressing the problematic use of pharmaceutical medications such as opioids.

UBC Assoc. Prof. Zach Walsh, co-author of the study.

UBC Assoc. Prof. Zach Walsh, co-author of the study.

In 2001, Canada became one of the first nations to develop a program to allow access to cannabis for medical purposes. As of August 2016 more than 30 federally authorized licensed producers of cannabis provided product to more than 65,000 patients.

“Further research into how well cannabis works compared to the accepted front-line treatments is warranted,” says Walsh. “Additionally, long-term research into the potential impact of the cannabis substitution on the quality of patient’s lives is ongoing.”

The study, published in International Journal of Drug Policy, was funded by Tilray.

—30—

Share this:

  • Email
  • Facebook
  • Twitter

Posted in Media Releases, Spotlight | Tagged Health, Irving K. Barber School of Arts and Sciences, Psychology, Research

  • Previous
  • Next

Contact

Christine Zeindler
Communications Specialist
University Relations

The University of British Columbia
Okanagan campus
Tel: 250 807 8470
E-mail: christine.zeindler@ubc.ca

See other posts by Christine Zeindler

UBC Okanagan Events

See what’s happening at UBC Okanagan. Explore the events calendar for performances, talks, workshops, community events, info sessions, and more.

View Events

Archives

UBC's Okanagan News
Okanagan Campus
3333 University Way
Kelowna, BC Canada V1V 1V7
Find us on
  
Back to top
The University of British Columbia
  • Emergency Procedures |
  • Terms of Use |
  • Copyright |
  • Accessibility
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.